Want to see GB:GENF full AI Analyst Report?
GENF Stock Chart & Stats
2.25 p
-0.02 p(-1.09%)
At close: 4:00 PM EST
2.25 p
-0.02 p(-1.09%)
Day’s Range― - ―
52-Week Range0.55 p - 3.12 p
Previous CloseN/A
Volume13.76K
Average Volume (3M)1.73M
Market Cap
£10.90M
Enterprise Value11.62M
Total Cash (Recent Filing)£111.79K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial DebtZero financial debt materially lowers refinancing and interest risks for a pre-revenue biotech. This structural flexibility lengthens runway options, reduces fixed cash outflows, and improves the company’s ability to prioritize R&D spend or negotiate equity-based partnerships without immediate debt service constraints.
Focused Gene‑based Ageing R&DA clear, science-driven focus on gene-based ageing therapies positions the company in a structural growth area: ageing biology and gene therapeutics. That specialization supports differentiated IP potential and long-term commercial optionality if programs translate, aligning with persistent demographic and biotech innovation trends.
Recent Operating ImprovementSequential improvement in free cash flow and narrower net losses suggests early execution progress or tighter cost discipline. For a cash-burning R&D firm, this durable trend can extend the financing runway, reduce near-term dilution risk, and indicate management responsiveness to capital constraints.
Bears Say
Pre‑revenue With Persistent Cash BurnThe company remains pre-revenue with multi-year operating losses and deeply negative operating and free cash flows, creating ongoing reliance on external financing. That structural cash-burn profile limits self-funding capacity, heightens dilution risk, and constrains long-term investment flexibility.
Negative Shareholders' EquityCumulative losses leading to negative equity are a durable red flag: they reduce balance-sheet resilience, complicate access to capital markets, and increase the probability of dilutive recapitalizations or restructuring if financing conditions tighten, affecting long-term financial stability.
Modest Asset Base And Small TeamA limited asset base and a very small employee count constrain internal development throughput and scale. For R&D-heavy biotech, this increases dependence on partnerships and external funding to advance trials, creating execution and capacity risk over the medium term.
Genflow Biosciences Plc News
GENF FAQ
What was Genflow Biosciences Plc’s price range in the past 12 months?
Genflow Biosciences Plc lowest share price was 0.55 p and its highest was 3.12 p in the past 12 months.
What is Genflow Biosciences Plc’s market cap?
Genflow Biosciences Plc’s market cap is £10.90M.
When is Genflow Biosciences Plc’s upcoming earnings report date?
Genflow Biosciences Plc’s upcoming earnings report date is Sep 25, 2026 which is in 71 days.
How were Genflow Biosciences Plc’s earnings last quarter?
Genflow Biosciences Plc released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Genflow Biosciences Plc overvalued?
According to Wall Street analysts Genflow Biosciences Plc’s price is currently Overvalued.
Does Genflow Biosciences Plc pay dividends?
Genflow Biosciences Plc does not currently pay dividends.
What is Genflow Biosciences Plc’s EPS estimate?
Genflow Biosciences Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genflow Biosciences Plc have?
Genflow Biosciences Plc has 566,409,800 shares outstanding.
What happened to Genflow Biosciences Plc’s price movement after its last earnings report?
Genflow Biosciences Plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.071%.
Which hedge fund is a major shareholder of Genflow Biosciences Plc?
Currently, no hedge funds are holding shares in GB:GENF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genflow Biosciences Plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Technical Analysis
Oxford BioDynamics
―
Physiomics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―